皇家华人

皇家华人
皇家华人 皇家华人
protein structures and brain images
Biophysics
Gang Cheng

Gang Cheng, PhD

Assistant Professor

Locations

  • Biophysics
    TBRC C0785

Contact Information

Education

PhD, Pharmacology, Shenyang Pharmaceutical University, Shenyang, China, 2005
BS, Pharmacy, Shandong University, Shandong, China, 1999

Research Interests

My current research interests focus on mitochondrial bioenergetics and redox metabolism in cancer cells. I have dedicated a significant portion of my research toward the wide range of metabolic and oxidative vulnerabilities that arise as consequences of the uncontrolled growth and proliferation capacities of cancer cells and toward the application of mitochondria-targeted compounds as potential selective anticancer drugs. We recently discovered that mitochondrial targeting of metformin can be improved by attaching a positively charged lipophilic triphenylphosphonium group; this results in a new class of mitochondria-targeted metformin analogues with significantly enhanced anticancer potential. The lead compound, mito-metformin, potently inhibits mitochondrial respiration through inhibition of complex I, stimulation of superoxide, formation of hydrogen peroxide, and activation of AMPK.

My research projects include the following:

  • Chemoprevention of Lung Cancer by Targeting Lonidamine to Mitochondria
  • Chemoprevention of Lung Cancer with Mitochondria-Targeted Honokiol

Publications

  • (Kalyanaraman B, Cheng G, Hardy M.) Arch Biochem Biophys. 2024 Oct 04:110172 PMID: 39369836 10/07/2024

  • (Cheng G, Hardy M, Hillard CJ, Feix JB, Kalyanaraman B.) Commun Biol. 2024 May 30;7(1):668 PMID: 38816577 PMCID: PMC11139878 SCOPUS ID: 2-s2.0-85194991828 05/31/2024

  • (Beerkens APM, Boreel DF, Nathan JA, Neuzil J, Cheng G, Kalyanaraman B, Hardy M, Adema GJ, Heskamp S, Span PN, Bussink J.) Cancer Metab. 2024 May 03;12(1):13 PMID: 38702787 PMCID: PMC11067257 05/04/2024

  • (Kalyanaraman B, Cheng G, Hardy M.) Redox Biol. 2024 May;71:103092 PMID: 38377788 PMCID: PMC10891329 SCOPUS ID: 2-s2.0-85185575430 02/21/2024

  • (Cheng G, Karoui H, Hardy M, Kalyanaraman B.) Free Radic Biol Med. 2023 Aug 20;205:175-187 PMID: 37321281 PMCID: PMC11129726 SCOPUS ID: 2-s2.0-85162228734 06/16/2023

  • (Cheng G, Hardy M, Kalyanaraman B.) Sci Rep. 2023 May 04;13(1):7254 PMID: 37142668 PMCID: PMC10160116 SCOPUS ID: 2-s2.0-85158068757 05/05/2023

  • (Cheng G, Karoui H, Hardy M, Kalyanaraman B.) Cancers (Basel). 2023 Feb 08;15(4) PMID: 36831432 PMCID: PMC9953882 02/26/2023

  • (Kalyanaraman B, Cheng G, Hardy M, You M.) Expert Opin Ther Targets. 2023;27(10):939-952 PMID: 37736880 PMCID: PMC11034819 SCOPUS ID: 2-s2.0-85173986031 09/22/2023

  • (Cheng G, Hardy M, You M, Kalyanaraman B.) Sci Rep. 2022 Mar 24;12(1):5143 PMID: 35332210 PMCID: PMC8948292 SCOPUS ID: 2-s2.0-85127039662 03/26/2022

  • (Kalyanaraman B, Cheng G, Hardy M.) Front Oncol. 2022;12:816504 PMID: 35756631 PMCID: PMC9214210 SCOPUS ID: 2-s2.0-85133350425 06/28/2022

  • (Cheng G, Hardy M, Topchyan P, Zander R, Volberding P, Cui W, Kalyanaraman B.) iScience. 2021 Jun 25;24(6):102673 PMID: 34189437 PMCID: PMC8215227 07/01/2021

  • (AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB.) iScience. 2021 Jun 25;24(6):102653 PMID: 34189432 PMCID: PMC8220235 07/01/2021

Publications of from the